Huizheng Technology

Huizheng Pharmaceutical, also known as Huizheng Technology, is a leading Chinese biopharmaceutical company and a core subsidiary of Zhejiang Hisun Pharmaceutical. Headquartered in Shanghai, the company serves as the innovative drug arm of the Hisun group, focusing on the research, clinical development, and commercialization of high-value therapeutics. Its portfolio spans critical therapeutic areas including oncology, cardiovascular health, anti-infectives, and immunology. Huizheng manages a diverse pipeline comprising internally developed biologics, such as next-generation antibody-drug conjugates (ADCs) and biosimilars, alongside in-licensed products from global pharmaceutical partners. The company leverages a sophisticated commercial infrastructure and professional medical affairs teams to navigate the complex Chinese healthcare landscape and deliver advanced medical solutions to patients.